A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose

M (Michel) van Agthoven; C Segeren; Ivonne Buijt; Carin Uyl - de Groot; Ronnie van der Holt; HM Lokhorst; Pieter Sonneveld

doi:10.1016/j.ejca.2004.01.019

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose

M (Michel) van Agthoven, C Segeren, Ivonne Buijt, Carin Uyl - de Groot, Ronnie van der Holt, HM Lokhorst, Pieter Sonneveld

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1159-1169
Number of pages	11
Journal	European Journal of Cancer
Volume	40
DOIs	https://doi.org/10.1016/j.ejca.2004.01.019
Publication status	Published - 2004

Access to Document

10.1016/j.ejca.2004.01.019

Cite this

van Agthoven, M., Segeren, C., Buijt, I., Uyl - de Groot, C., van der Holt, R., Lokhorst, HM., & Sonneveld, P. (2004). A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose. European Journal of Cancer, 40, 1159-1169. https://doi.org/10.1016/j.ejca.2004.01.019

van Agthoven, M (Michel) ; Segeren, C ; Buijt, Ivonne et al. / A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose. In: European Journal of Cancer. 2004 ; Vol. 40. pp. 1159-1169.

@article{5206591fd3694a26a9d52097e6a1284c,

title = "A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose",

author = "{van Agthoven}, {M (Michel)} and C Segeren and Ivonne Buijt and {Uyl - de Groot}, Carin and {van der Holt}, Ronnie and HM Lokhorst and Pieter Sonneveld",

year = "2004",

doi = "10.1016/j.ejca.2004.01.019",

language = "Undefined/Unknown",

volume = "40",

pages = "1159--1169",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

van Agthoven, M, Segeren, C, Buijt, I, Uyl - de Groot, C , van der Holt, R, Lokhorst, HM & Sonneveld, P 2004, 'A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose', European Journal of Cancer, vol. 40, pp. 1159-1169. https://doi.org/10.1016/j.ejca.2004.01.019

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose. / van Agthoven, M (Michel); Segeren, C; Buijt, Ivonne et al.
In: European Journal of Cancer, Vol. 40, 2004, p. 1159-1169.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose

AU - van Agthoven, M (Michel)

AU - Segeren, C

AU - Buijt, Ivonne

AU - Uyl - de Groot, Carin

AU - van der Holt, Ronnie

AU - Lokhorst, HM

AU - Sonneveld, Pieter

PY - 2004

Y1 - 2004

U2 - 10.1016/j.ejca.2004.01.019

DO - 10.1016/j.ejca.2004.01.019

M3 - Article

SN - 0959-8049

VL - 40

SP - 1159

EP - 1169

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

van Agthoven M, Segeren C, Buijt I, Uyl - de Groot C , van der Holt R, Lokhorst HM et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemd patients with stage II/III multiple myeloma: a prospective randomised phototherapy with autologous stem-cell rescue in a newly diagnose. European Journal of Cancer. 2004;40:1159-1169. doi: 10.1016/j.ejca.2004.01.019